Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Aug 23;9(2):141-145.
doi: 10.1159/000475519. eCollection 2017 May-Aug.

Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis

Ganesh Pai  1 , Anusha H Pai  1
Affiliations
Case Reports

Itolizumab - A New Biologic for Management of Psoriasis and Psoriatic Arthritis

Ganesh Pai et al. Case Rep Dermatol. .

Abstract

Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The available treatment options to cure psoriasis include topical therapy, phototherapy, and biological therapy. Biological therapy has become a promising option due to the rapid action and less adverse effects associated with its use. The newly developed biologic itolizumab is a humanized recombinant anti-CD6 monoclonal antibody of IgG1 isotype that binds to domain 1 of CD6, thereby immunomodulating human lymphocytes without interfering with the binding of CD6 to the activated leukocyte-cell adhesion molecule. In this case series, a total of 5 patients with chronic plaque psoriasis were treated with itolizumab. They exhibited a rapid PASI 75 response after 4 doses of itolizumab infusion. The patients were poor responders to methotrexate and/or cyclosporine therapy for a long time. All infusions were well tolerated by all patients with no adverse reactions or infections during the treatment period. Itolizumab can be a good option for management of psoriasis and psoriatic arthritis.

Keywords: Itolizumab; Psoriasis; Psoriatic arthritis.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Effect of itolizumab treatment on psoriasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64:ii87–ii90. - PMC - PubMed
    1. Lazaro EA, Lopez-Requena A, Fuentes D, et al. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs. 2014;6:782–792. - PMC - PubMed
    1. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;61:451–485. - PubMed
    1. Menon R, David BG. Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Clin CosmetInvestig Dermatol. 2015;8:215–222. - PMC - PubMed
    1. Sivamani RK, Correa G, Ono Y, et al. Biological therapy of psoriasis. Indian J Dermatol. 2010;55:161–170. - PMC - PubMed

Publication types